|
Synonyms: humZ270 [8] | IPH-2201 | NN8765-3658
Compound class:
Antibody
Comment: Monalizumab (IPH2201) is a humanized IgG4κ anti-NKG2A (KLRC1, CD159a) monoclonal antibody being investigated as an anti-cancer treatment [4,7]. Administered intravenously or subcutaneously. Use of monalizumab is claimed in patent WO2016041947 (called IPH2201 in the patent) [1].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Andre P, Blery M, Paturel C, Soulas C, Wagtmann N. (2016)
Treatment regimens using anti-nkg2a antibodies. Patent number: WO2016041947. Assignee: Innate Pharma. Priority date: 16/09/2014. Publication date: 24/03/2016. |
|
2. Derré L, Corvaisier M, Charreau B, Moreau A, Godefroy E, Moreau-Aubry A, Jotereau F, Gervois N. (2006)
Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J Immunol, 177 (5): 3100-7. [PMID:16920947] |
|
3. Godal R, Bachanova V, Gleason M, McCullar V, Yun GH, Cooley S, Verneris MR, McGlave PB, Miller JS. (2010)
Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade. Biol Blood Marrow Transplant, 16 (5): 612-21. [PMID:20139023] |
|
4. Innate Pharma.
IPH2201: first-in-class anti-NKG2A mAb. Accessed on 27/04/2015. Modified on 27/04/2015. http://innate-pharma.com, http://innate-pharma.com/en/product-pipeline/iph2201-first-class-anti-nkg2a-mab |
|
5. Levy EM, Bianchini M, Von Euw EM, Barrio MM, Bravo AI, Furman D, Domenichini E, Macagno C, Pinsky V, Zucchini C et al.. (2008)
Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer. Int J Oncol, 32 (3): 633-41. [PMID:18292941] |
|
6. Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, Gonçalves A, André P, Romagné F, Thibault G et al.. (2011)
Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest, 121 (9): 3609-22. [PMID:21841316] |
|
7. McWilliams EM, Mele JM, Cheney C, Timmerman EA, Fiazuddin F, Strattan EJ, Mo X, Byrd JC, Muthusamy N, Awan FT. (2016)
Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia. Oncoimmunology, 5 (10): e1226720. [PMID:27853650] |
|
8. Ruggeri L, Urbani E, André P, Mancusi A, Tosti A, Topini F, Bléry M, Animobono L, Romagné F, Wagtmann N et al.. (2016)
Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells. Haematologica, 101 (5): 626-33. [PMID:26721894] |
|
9. Silva TG, Crispim JC, Miranda FA, Hassumi MK, de Mello JM, Simões RT, Souto F, Soares EG, Donadi EA, Soares CP. (2011)
Expression of the nonclassical HLA-G and HLA-E molecules in laryngeal lesions as biomarkers of tumor invasiveness. Histol Histopathol, 26 (12): 1487-97. [PMID:21972088] |
